METFORMIN TREATMENT IMPACTS ON BEHAVIOR, NEUROCHEMICAL AND METABOLIC PARAMETERS OF LDLR-/- MICE

Familial hypercholesterolemia (FH) is a prevalent disease caused by dysfunctions of the low-density lipoprotein receptor (LDLr), and several reports show its connection to the blood-brain barrier (BBB) and neuroinflammation. Recent studies associate mTOR inhibition with conservation of BBB integrity, cognitive damage attenuation, and systemic and cerebral inflammation reduction in dementia and FH animal models. In this regard, Metformin presents critical therapeutic potential because it inhibits mTOR through AMPK.